This trial is designed to evaluate the long-term safety and efficacy of a growth hormone deficiency treatment administered once-weekly. The study participants are adults (males and females) who have completed the treatment period in a previous study.
- Adult Onset Growth Hormone Deficiency
- Endocrine Disorders
- Hormone Deficiency
1 Primary · 5 Secondary · Reporting Duration: Week 52
Awards & Highlights
1 Treatment Group
1 of 1
240 Total Participants · 1 Treatment Group
Primary Treatment: Lonapegsomatropin · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 23 - 81 · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What is the efficacy of Lonapegsomatropin in previous clinical trials?
"At this moment, there are 2 concurrent clinical trials testing Lonapegsomatropin. These studies have reached Phase 3 and are being conducted in 56 different locations." - Anonymous Online Contributor
Would this experiment be interested in participants who are over 30 years old?
"According to the inclusion criteria found on this clinical trial's website, 23 studies are for people under 18 years old and 28 are for patients 65 and older." - Anonymous Online Contributor
What is the FDA's assessment of Lonapegsomatropin?
"Given that this is a Phase 3 trial, our team has determined that the Lonapegsomatropin drug intervention is safe (scoring a 3 on our 1-3 scale). There is efficacy data as well as multiple rounds of safety data supporting this assumption." - Anonymous Online Contributor